Director Ilan Ganot (SLDB) reports new stock options, RSUs and updated holdings

Rhea-AI Filing Summary

Solid Biosciences director Ilan Ganot reported several equity compensation events and updated holdings. On January 29, 2026, an entity associated with his wife received an employee stock option for 70,900 shares of common stock at an exercise price of $6.6 per share, vesting over four years. On the same date, his wife was also granted 35,450 restricted stock units (RSUs), which vest in four equal annual installments.

On January 31, 2026, 15,000 RSUs associated with his wife were settled into 15,000 shares of common stock, increasing her indirect common stock holdings to 32,476 shares and RSU holdings to 45,000 units. Separately, Ganot directly and jointly holds 99,297 shares of common stock and an additional 19,394 shares are held in the Ilan Ganot 2017 Irrevocable Trust.

Insider Trade Summary

15,000 shares exercised/converted

Mixed 6 txns

Insider Ganot Ilan

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	15,000	$0.00	--
Exercise	Common Stock	15,000	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	70,900	$0.00	--
Grant/Award	Restricted Stock Units	35,450	$0.00	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 45,000 shares (Indirect, Wife); Common Stock — 32,476 shares (Indirect, Wife); Employee Stock Option (Right to Buy) — 70,900 shares (Indirect, Wife); Common Stock — 99,297 shares (Direct)

Footnotes (1)

1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Represents 95,255 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Represents 19,394 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017. This option was granted on January 29, 2026 (the "2026 Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary. The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary. On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 60,000 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ganot Ilan

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		M		15,000	A	(1)	32,476	I	Wife
Common Stock								99,297	D(2)
Common Stock								19,394	I	See Footnote 3(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$6.6	01/29/2026		A		70,900		(4)	01/29/2036	Common Stock	70,900	$0	70,900	I	Wife
Restricted Stock Units	(1)	01/29/2026		A		35,450		(5)	(5)	Common Stock	35,450	$0	35,450	I	Wife
Restricted Stock Units	(1)	01/31/2026		M			15,000	(6)	(6)	Common Stock	15,000	$0	45,000	I	Wife

Explanation of Responses:

1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

2. Represents 95,255 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship.

3. Represents 19,394 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.

4. This option was granted on January 29, 2026 (the "2026 Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.

5. The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.

6. On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 60,000 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary

	/s/ Kimberly Cornwell as attorney-in-fact for Ilan Ganot	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Ilan Ganot report for Solid Biosciences (SLDB)?

Ilan Ganot reported new equity awards and RSU vesting tied to his wife. These include stock options and restricted stock units that increase indirect exposure to Solid Biosciences common stock, along with an update of his direct, joint, and trust common stock holdings.

How many stock options tied to Solid Biosciences (SLDB) were granted to Ilan Ganot’s wife?

An entity associated with Ilan Ganot’s wife received an employee stock option for 70,900 shares at a $6.6 exercise price. The option vests over four years, with 25% after one year and the remainder vesting monthly until the fourth anniversary.

What new restricted stock units did Ilan Ganot’s wife receive in Solid Biosciences (SLDB)?

On January 29, 2026, Ilan Ganot’s wife was granted 35,450 restricted stock units in Solid Biosciences. These RSUs vest over four years, with 25% of the original grant vesting on each anniversary of the January 29, 2026 grant date until the fourth anniversary.

How many Solid Biosciences (SLDB) RSUs vested and converted to shares on January 31, 2026?

On January 31, 2026, 15,000 restricted stock units associated with Ilan Ganot’s wife vested and converted into 15,000 shares of Solid Biosciences common stock. These RSUs came from a 60,000-unit grant made on January 31, 2025, vesting in four equal annual installments.

What are Ilan Ganot’s direct and joint common stock holdings in Solid Biosciences (SLDB)?

Ilan Ganot beneficially owns 95,255 Solid Biosciences shares directly and 4,042 shares jointly with Annie Ganot as joint tenants with right of survivorship. Together, these positions total 99,297 common shares reported as directly beneficially owned after the transactions.

How many Solid Biosciences (SLDB) shares are held in the Ilan Ganot 2017 Irrevocable Trust?

The Ilan Ganot 2017 Irrevocable Trust holds 19,394 shares of Solid Biosciences common stock. These shares are held by Adam Ganot and Annie Ganot, and their successors, as trustees under the March 3, 2017 trust arrangement benefiting Ilan Ganot.

How many Solid Biosciences (SLDB) RSUs remain outstanding for Ilan Ganot’s wife after the reported transactions?

After the January 31, 2026 RSU conversion, Ilan Ganot’s wife holds 45,000 outstanding restricted stock units. These include remaining tranches from a 60,000-unit grant dated January 31, 2025 and a new 35,450-unit grant dated January 29, 2026, both vesting in annual installments.